Skip to main content
SpringerLink
Log in
Book cover

Textbook of Rare Sexual Medicine Conditions pp 51–63Cite as

Post-SSRI Sexual Dysfunction (PSSD)

  • Chapter
  • First Online:

Abstract

Antidepressant treatment with SSRIs and SNRIs can have negative influences on all stages of the sexual response cycle. In some individuals, the impairments in sexual functioning and sexual satisfaction continue long after the medication is stopped, for which the term “Post-SSRI Sexual Dysfunction” (PSSD) is used to describe this disorder. PSSD is unrelated to any pre-existing or reactive mental health issue, medical condition, or substance abuse. PSSD is difficult to diagnose and should be done by analysing the patient’s drug history, the onset of symptoms, and sexual function before starting such a medication. Key symptoms are genital anaesthesia, erectile dysfunction, and pleasureless orgasm. As the pathophysiology of the disorder is unknown, there are no curative treatments available. However, some management approaches are suggested to cope with the impact of the symptoms on sexuality and the quality of life of those bothered by PSSD. Medical recognition of PSSD is critical for obtaining the resources needed to investigate the true prevalence of the disorder, its pathophysiological mechanism(s), and potential treatments.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   84.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Bala A, Nguyen HMT, Hellstrom WJG. Post-SSRI sexual dysfunction: a literature review. Sex Med Rev. 2018;6(1):29–34. https://doi.org/10.1016/j.sxmr.2017.07.002.

    Article  PubMed  Google Scholar 

  2. Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgrad Med. 2014;126(2):91–9. https://doi.org/10.3810/pgm.2014.03.2744.

    Article  PubMed  Google Scholar 

  3. Healy D, Le Nourya J, Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med. 2018;29:125–34. https://doi.org/10.3233/JRS-180744.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Reisman Y. Post-SSRI sexual dysfunction. BMJ. 2020;368:m754. https://doi.org/10.1136/bmj.m754.

    Article  PubMed  Google Scholar 

  5. Bahrick A. Post SSRI sexual dysfunction. Am Soc Adv Pharmacother Tablet. 2006;163:1504–9.

    Google Scholar 

  6. Csoka AB, Shipko S. Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom. 2006;75:187–8. https://doi.org/10.1159/000091777.

    Article  PubMed  Google Scholar 

  7. Reisman Y. Sexual consequences of post-SSRI syndrome. Sex Med Rev. 2017;5(4):429–33. https://doi.org/10.1016/j.sxmr.2017.05.002.

    Article  PubMed  Google Scholar 

  8. https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_en.pdf.

    Google Scholar 

  9. Healy D, Bahrick A, Maarten B et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022;33(1):65–76. https://doi.org/10.3233/JRS-210023.

  10. Healy D, Le Nourya J, Mangin D. Post-SSRI sexual dysfunction: patient experiences of engagement with healthcare professionals. Int J Risk Saf Med. 2019;30:167–78. https://doi.org/10.3233/JRS-191005.

    Article  PubMed  Google Scholar 

  11. Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiat. 2018;75(4):336–46. https://doi.org/10.1001/jamapsychiatry.2017.4602.

    Article  Google Scholar 

  12. Reisman Y. Are there any sex/gender differences in post-selective serotonin reuptake inhibitors (SSRI) sexual dysfunction (PSDD)? Curr Sex Health Rep. 2019;11:237–42. https://doi.org/10.1007/s11930-019-00222-x.

    Article  Google Scholar 

  13. Bolton JM, Sareen J, Reiss JP. Genital anesthesia persisting six years after sertraline discontinuation. J Sex Marital Ther. 2006;32(4):327–30. https://doi.org/10.1080/00926230600666410.

    Article  PubMed  Google Scholar 

  14. Kauffman RP, Murdock A. Prolonged post-treatment genital anesthesia and sexual dysfunction following discontinuation of citalopram and the atypical antidepressant nefazodone. Open Women’ Health J. 2007;1:1–3. https://doi.org/10.1258/ijsa.2008.008402.

    Article  CAS  Google Scholar 

  15. Csoka AB, Bahrick AS, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors (SSRIs). J Sex Med. 2008;5:227–33. https://doi.org/10.1111/j.1743-6109.2007.00630.x.

    Article  CAS  PubMed  Google Scholar 

  16. Ekhart GC, Van Puijenbroek EP. Blijvende seksuele functiestoornissen na staken van een SSRI? Tijdschr Psychiatr. 2014;56:336–40.

    CAS  PubMed  Google Scholar 

  17. Stinson RD. The impact of persistent sexual side effects of selective serotonin reuptake inhibitors after discontinuing treatment: a qualitative study. PhD (Doctor of Philosophy) thesis, University of Iowa, 2013. http://ir.uiowa.edu/etd/5061.

  18. Hogan C, Le Noury J, Healy D, Mangin D. One hundred and twenty cases of enduring sexual dysfunction following treatment. Int J Risk Saf Med. 2014;26(2):109–16. https://doi.org/10.3233/JRS-140617.

    Article  PubMed  Google Scholar 

  19. Waldinger MD, van Coevorden RS, Schweitzer DH, Georgiadis J. Penile anesthesia in post SSRI sexual dysfunction (PSSD) responds to low-power laser irradiation: a case study and hypothesis about the role of transient receptor potential (TRP) ion channels. Eur J Pharmacol. 2015;753:263–8. https://doi.org/10.1016/j.ejphar.2014.11.031.

    Article  CAS  PubMed  Google Scholar 

  20. Ben-Sheetrit J, Aizenberg D, Csoka AB, et al. Post-SSRI sexual dysfunction clinical characterization and preliminary assessment of contributory factors and dose-response relationship. Clin Psychopharmacol. 2015;35:1–6. https://doi.org/10.1097/JCP.0000000000000300.

    Article  CAS  Google Scholar 

  21. Reisman Y, Jannini TB, Jannini EA. Post-SSRI sexual dysfunctions (PSSD). Retrospective clinical experience with patients treated with a multimodal approach. J Men’s Health 2022.

    Google Scholar 

  22. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc Patient Saf. 2010;2:141–50. https://doi.org/10.2147/DHPS.S7634.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6:1506–33. https://doi.org/10.1111/j.1743-6109.2009.01309.

  24. Montejo AL, Montejo L, Navarro-Cremades F. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry. 2015;28(6):418–23. https://doi.org/10.1097/YCO.0000000000000198.

    Article  PubMed  Google Scholar 

  25. González Catuela BV, Quintana GR, Ackerman J, et al. Acute caffeine reverses the disruptive effects of chronic fluoxetine on the sexual behavior of female and male rats. Psychopharmacology. 2021;238:755–64. https://doi.org/10.1007/s00213-020-05728-0.

    Article  CAS  Google Scholar 

  26. Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013;27:703–16. https://doi.org/10.1007/s40263-013-0071-0.

    Article  CAS  PubMed  Google Scholar 

  27. Kumar A, Russell RM, Pifer R, et al. The serotonin neurotransmitter modulates virulence of enteric pathogens. Cell Host Microbe. 2020;28(1):41–53.e8. https://doi.org/10.1016/j.chom.2020.05.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Alboni S, van Dijk RM, Poggini S, et al. Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. Mol Psychiatry. 2017;22:635. https://doi.org/10.1038/mp.2015.191.

    Article  CAS  PubMed  Google Scholar 

  29. Coskuner ER, Culha MG, Ozkan B, Kaleagasi EO. Post-SSRI sexual dysfunction: preclinical to clinical. Is it fact or fiction? Sex Med Rev. 2018;6(2):217–23. https://doi.org/10.1016/j.sxmr.2017.11.004.

    Article  PubMed  Google Scholar 

  30. Simonsen AL, Danborg PB, Gotzsche PC. Persistent sexual dysfunction after early exposure to SSRIs: systematic review of animal studies. Int J Risk Saf Med. 2016;28:1–12. https://doi.org/10.3233/JRS-160668.

    Article  PubMed  Google Scholar 

  31. Maciag D, Simpson KL, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology. 2006;31:47–57. https://doi.org/10.1038/sj.npp.1300823.

    Article  CAS  PubMed  Google Scholar 

  32. Sukoff Rizzo SJ, Pulicicchio C, Malberg JE, et al. 5-HT1A receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats. Int J Neuropsychopharmacol. 2009;12:1045–53. https://doi.org/10.1017/S1461145709000406.

    Article  CAS  PubMed  Google Scholar 

  33. Coleman CC, Cunningham LA, Foster VJ. Sexual dysfunction associated with the treatment of depression: a placebo controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry. 1999;11:205–15. https://doi.org/10.1023/a:1022309428886.

    Article  CAS  PubMed  Google Scholar 

  34. Clayton A, Warnock J, Kornstein S, et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 2004;65:62–7. https://doi.org/10.4088/jcp.v65n0110.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Flare Health, Amstelveen, The Netherlands

    Yacov Reisman

  2. Czech National Institute of Mental Health, Laboratory of Sexual Neuroscience, Klecany, Czech Republic

    James G. Pfaus

  3. Department of Gynecology, Galilee Medical Center, Nahariya, Israel

    Lior Lowenstein

Authors
  1. Yacov Reisman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James G. Pfaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lior Lowenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yacov Reisman .

Editor information

Editors and Affiliations

  1. Flare Health, Amstelveen, The Netherlands

    Yacov Reisman

  2. Department of Gynecology, Galilee Medical Center, Nahariya, Israel

    Lior Lowenstein

  3. Institute of Clinical Sexology, Rome, Italy

    Francesca Tripodi

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Reisman, Y., Pfaus, J.G., Lowenstein, L. (2022). Post-SSRI Sexual Dysfunction (PSSD). In: Reisman, Y., Lowenstein, L., Tripodi, F. (eds) Textbook of Rare Sexual Medicine Conditions. Springer, Cham. https://doi.org/10.1007/978-3-030-98263-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-98263-8_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-98262-1

  • Online ISBN: 978-3-030-98263-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation